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Minocycline as an adjunct for treatment-
resistant depressive symptoms: study protocol
for a pilot randomised controlled trial
Muhammad I. Husain1*, Imran B. Chaudhry2, Raza R. Rahman3, Munir M. Hamirani4, Inti Qurashi5, Ameer B. Khoso6,
John FW Deakin7, Nusrat Husain7 and Allan H. Young1
Abstract
Background: Depression is one of the leading causes of disability worldwide. A high proportion of patients do not
respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may have
beneficial effects in major depression. Minocycline is a tetracycline antibiotic with good CNS penetration that exerts
effects on multiple interacting symptoms implicated in the pathophysiology of mood disorders. Open-label studies
have suggested that minocycline is effective as an adjunct drug in improving depressive symptoms.
Methods/Design: This is a multi-centre, 3-month, double-blind, placebo-controlled, pilot trial of minocycline added
to treatment as usual for patients suffering from DSM-IV major depressive disorder. This will be a double-blind,
randomised, controlled, two parallel-arm study with 20 participants in each arm, giving a total of 40 participants.
There will be a screening visit, a randomization visit and four follow-up visits. Clinical assessments using the
Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression scale (CGI), Patient Health Questionnaire-9
(PHQ −9) and the Generalised Anxiety Disorder scale (GAD-7) will be carried out at every visit. Side effects checklists
will also be undertaken at each visit. Biomarkers (inflammatory cytokines and CRP) will be measured at baseline and
at the end of the treatment phase. Minocycline will be started at 100 mg once daily (OD) and will be increased to
200 mg at two weeks.
Discussion: Anti-inflammatory treatments have been shown to have some beneficial effects in the treatment of
major depressive disorder. The aim of this pilot randomised controlled trial is to establish the degree of
improvement in depressive symptoms with the addition of minocycline to treatment as usual.
Trial registration: ClinicalTrials.gov NCT02263872 registered 10 October 2014.
Keywords: Depression, Major depressive disorder, Minocycline, Anti-inflammatory
Background
Major depressive disorder is associated with significant
morbidity and mortality. Depression is the leading cause of
disability worldwide in terms of years lost due to disability
[1]. Although depressive symptoms are amenable to anti-
depressant treatment, a high proportion of patients neither
responds adequately nor achieves remission. For example
in the Sequenced Treatment Alternatives for the Relief of
Depression (STAR*D) study, the response and remission
rates with stage 1 treatment (citalopram) were 49 and 37 %,
respectively. The further response rates decreased to 16
and 13 %, respectively, over the subsequent next three
treatment steps [2]. More recently, a systematic review of
the efficacy of current pharmacological treatments of de-
pressive disorder in primary care showed only a relatively
small effect size for antidepressant treatments when com-
pared with the placebo [3]. Thus, there remains a clear
need for exploring novel treatment approaches.
Recently, there have been promising preclinical and
clinical data linking inflammatory processes to a range
of psychiatric illness including depression. The evidence
* Correspondence: ishrat-h@doctors.net.uk
1Centre for Affective Disorders, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF,
UK
Full list of author information is available at the end of the article
TRIALS
© 2015 Husain et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Husain et al. Trials  (2015) 16:410 
DOI 10.1186/s13063-015-0933-5
that depression (or some subgroups thereof ) is an
inflammatory-related disorder comes from multiple
sources, including the observation that depression is
associated with raised inflammatory markers in the
absence of a medical illness [4]. More specifically,
depression has been associated with higher levels of
positive acute phase proteins (APPs) and low levels
of negative APPs [5], as well as increased levels of com-
plement factors C3c and C4 and immunoglobulin M (IgM)
and IgG [6]. Inflammatory medical illnesses, both CNS and
peripheral, are associated with greater rates of depression
and in patients with Crohn’s disease and comorbid depres-
sion, bouts of physical disease activity tend to co-occur with
depressive episodes [7]. Furthermore, patients treated with
cytokines for various illnesses have an increased risk of
developing depressive illness [8]. For example, treatment
with cytokine IFN-α corresponded with the development
of depressive symptoms in up to 45 % of patients [9].
The available evidence suggests that the addition of an
anti-inflammatory medication may be efficacious in the
treatment of depressive illness. Muller et al. [10] dem-
onstrated a reduction in depressive symptoms when
using Celecoxib, a COX-2 selective non-steroidal anti-
inflammatory drug, in addition to Reboxetine, for the
treatment of major depressive disorder in a double-blind,
randomised, placebo-controlled pilot study. A recent meta-
analysis showed that augmentation with Celecoxib is an
effective add-on treatment for unipolar depressive patients
[11]. However, other studies have found that anti-
inflammatories may have an antagonistic effect on the
antidepressant actions of SSRIs [12]. Further work is
needed in this area to clarify the role of inflammatory
processes and anti-inflammatories in the treatment of
depression.
The tetracycline antibiotic minocycline has been
proposed for the treatment of depressive symptoms as
well as negative symptoms in schizophrenia [13, 14].
Preliminary data from an open-label study of patients with
psychotic unipolar depression suggested that minocycline
augmentation of antidepressant treatment was effective and
well tolerated [15]. Minocycline is a pleiotropic agent that
exerts effects on multiple interacting systems (that is, anti-
inflammatory, anti-oxidant, anti-apoptotic, glutamatergic
and monaminergic) implicated in the pathophysiology of
mood disorders. Despite such neuroprotective properties,
there have been no published clinical trials to date
investigating the antidepressant effects of minocycline
in individuals with major depressive disorder.
In this double-blind, randomised, controlled pilot trial,
we will determine the efficacy of minocycline as an adjunct
to treatment as usual (TAU) in patients with major depres-
sive disorder. We hypothesise that minocycline augmenta-
tion will lead to an improvement in depressive symptoms
in participants in comparison with the placebo.
Aim
The aim of this study is to investigate whether the addition
of minocycline to treatment as usual (TAU) for 3 months
in patients with major depressive disorder will lead to an
improvement in depressive symptoms compared with TAU.
Methods/Design
Overview
This is a multi-centre, 12-week, double-blind, placebo-
controlled, pilot trial of minocycline added to treatment as
usual for patients suffering from DSM-IV major depressive
disorder. It will be a double-blind, randomised, controlled,
two parallel-arm study with 20 participants in each arm,
giving a total of 40 participants. The study will be con-
ducted in Karachi, Pakistan, and participants will be
recruited from outpatient psychiatric clinics at the fol-
lowing units: the Karwan-e-Hayat Hospital, Abbasi
Shaheed Hospital, Civil Hospital Karachi and Institute
of Behavioural Science, Karachi.
All patients will give written informed consent after
reading the information provided in Urdu. Treatment as
usual (TAU) will comprise medications including antide-
pressants (SSRI’s, Tricyclics, MAOIs, and SNRIs), mood
stabilisers (with the exception of valproic acid) and anti-
psychotics, as well as psychotherapy and other psycho-
social interventions.
Randomisation and masking
Tablets will be dispensed by a single pharmacy in
Karachi according to separate computerised random-
isation lists generated using an online randomisation
tool (www.randomisation.com) and will be held by a
central pharmacist in Pakistan. There will be no further
stratification.
Patients, their families, referring psychiatrists and the
research assistants carrying out the assessments will be
blind to the study drug until the completion of the study.
Reign Nutro Pharma and Jawed Traders (Pakistan) will
provide minocycline and placebo in identical tablet form,
matched both for colour and size.
Sample size
Participants will be randomly divided into two groups: the
intervention group and treatment-as-usual group. A total
of forty participants will be recruited and divided equally
into two arms. This is a pilot trial, and therefore, the sample
size is sufficient for a study of this nature. Assuming an
attrition rate of 10 %, we are confident that we will have at
least 18 subjects per group for analysis at the end of the
trial. The U.S. Food and Drug Administration guidance on
drug study design recommends that a minimum of 12 sub-
jects per group is sufficient for pilot trials [16].
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Power calculation
In the proposed study, a group size of 18 participants is
powered at 0.75 and an alpha of 0.05 to detect an effect size
of 0.75 in the reduction of Hamilton Depression scores
(HAM-D) [17] between the minocycline and treatment as
usual. At present, there are no clinical trials of minocycline
in the treatment of unipolar or bipolar depression; there-
fore, a true population effect size is currently unknown.
However in clinical trials with antidepressants, an effect
size of 0.40 or higher is considered a clinically significant
response criterion [18].
Local research ethics committee approval
Institutional review board (IRB) approval has been ob-
tained from the ethics committee of the Karachi Medical
and Dental College and Dow University of Health Sciences,
Pakistan.
Inclusion criteria
Inclusion criteria are (1) patients aged 18 to 65 years, (2)
Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis
of major depressive disorder, (3) competent and willing to
give informed consent, (4) taking the current antidepres-
sant medication for a minimum of 4 weeks (6 weeks for
Fluoxetine) prior to baseline, (5) the current episode of
depression has failed to remit with at least two courses of
antidepressant treatment (one of which is the current
course), (6) able to take oral medication and (7) if female,
willing to use adequate contraceptive precautions and to
have monthly pregnancy tests.
Exclusion criteria
Exclusion criteria are (1) relevant medical illness (renal,
hepatic, cardiac, serious dermatological disorders such
as exfoliative dermatitis, systemic lupus erythematosis),
(2) prior history of intolerance to any of the tetracyclines,
(3) concomitant penicillin therapy, (4) concomitant anti-
coagulant therapy, (5) presence of a seizure disorder, (6)
currently taking valproic acid, (7) any change of psycho-
tropic medications within the previous 4 weeks, (8) diag-
nosis of substance abuse (except nicotine or caffeine) or
dependence within the last 3 months according to DSM-
IV criteria, (9) pregnant or breast-feeding or (10) presence
of primary psychotic disorder.
The criteria for leaving the trial are (1) patient’s request,
(2) at the discretion of the responsible medical officer or
investigator (for example, an adverse event or poor compli-
ance) and (3) pregnancy.
Study procedure
Recruitment
The psychiatry consultants responsible for patient care will
be approached and asked if they will allow their patients to
take part in this research study.
In the first instance, the research clinician will approach
the clinical teams to inform them about the research
study, especially with regard to inclusion and exclusion
criteria. The research clinician will establish good working
relationships with the individual clinical teams. They will be
in regular contact either by phone or by visits to determine,
in collaboration with the clinical team, if the patients are
suitable to take part in the research study. If patients meet
the entry criteria, are clinically stable and the consultant
psychiatrist and the clinical team agree the patient could be
a possible participant, the consultant will introduce the
study to the patient. With the patient’s agreement, the
research clinician will visit the patient to explain the
research study verbally and provide them with the
patient information sheet. After the patient has had time
to read and understand the patient information sheet (at
least 24 h) and is willing to take part, a meeting (visit one)
will be set up with the patient in order to obtain signed
informed consent for the research and also signed consent
for the research team to have access to their medical notes.
Screening visit
Confirmation of patient suitability will be carried out at this
point. Participants recruited to the trial will undergo struc-
tured diagnostic interviews using the Mini International
Neuropsychiatric Interview (MINI) to confirm a diagnosis
of DSM-IV major depressive disorder [19]. This tool has
been validated for use in the local Urdu language and
has been used in previous studies [20]. The Hamilton
Depression Scale (HAMD-17) [17] will be used to measure
severity and response and is not being utilised as a screen-
ing tool for this study and therefore there is no specific
HAMD-17 score required for study inclusion. Other In-
clusion/Exclusion criteria will be checked at this visit and
confirmation of consent and pregnancy testing, if appro-
priate will be carried out.
Follow-up
Participants will be randomised to receive minocycline
or treatment as usual (TAU). Patients will continue with
their current antidepressant treatment prescribed by
their psychiatrists. Minocycline added to TAU will start
at a dose of 100 mg daily and will be increased after two
weeks to 200 mg daily, taken as a single dose to encour-
age compliance.
The patients’ day-to-day care will remain the responsibil-
ity of the consultant psychiatrist or other mental health
professional in charge of the patient. However, research as-
sistants will maintain contact throughout the study in order
to respond to any concerns or changes in circumstances or
mental or physical state. Contacts will be 2-weekly for the
duration of the study. Any study-related safety concerns
will be the responsibility of the co-investigators who can be
contacted at any time through the research team.
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Outcome measures
The primary clinical outcome measures will be mean
change from baseline to week 12 on the Hamilton Depres-
sion Scale scores [17]. Response is defined as a reduction
of 50 % or more of the HAMD-17. Remission is defined
as a score of ≤7 of the HAMD-17.
Ratings will be made on the basis of a semi-structured
clinical interview at baseline, weeks 2, 4, 8 and 12.
The secondary clinical outcome measures will be the
Clinical Global Impression (CGI) scale, a 7-point overall
measure of severity; the PHQ −9 [21], a depression sever-
ity measure; and the GAD-7 [22], a measure of generalised
anxiety disorder. These instruments have been used in a
previous clinical trial in Pakistan [23]. Participants will
also complete the Mood Disorder Questionnaire (MDQ)
[24], a brief self-report questionnaire to screen for bipolar
disorder. Adverse effects will be monitored using a rating
scale that has been specifically designed for minocycline.
This rating scale has been used by the authors in previous
studies [14].
Biomarkers
Participants will be asked to provide two blood samples
for research analysis. The provision of blood samples is
optional and does not affect participation in the trial.
These samples will be collected at baseline and at week 12.
The samples will be collected to investigate the relation of
the minocycline to the inflammatory markers and if this
relates to the subjective experience of symptom change.
The biomarkers tested include complete blood count,
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP).
Research assistant training and inter-rater reliability
Research assistants in Karachi were trained in Structured
Clinical Interview for DSM-IV (SCID) and clinical assess-
ments at the University of Manchester for a previous
grant-funded study. Interrater reliability will be measured
throughout the study by local PIs. To establish inter-rater
reliability training videos will be used while two raters code
them independently. SPSS will then be used to calculate the
Intraclass Correlation Coefficient.
Statistical analysis
All analyses will be based, as far as possible, on the
intention-to-treat principle (with weighting adjustments
to allow for differential loss to follow-up). Primary and
secondary outcomes will be measured using a mixed-
effects model (ANCOVA).
Study coordination
The study will be coordinated through weekly meetings
by local investigators. There will be two weekly tele- or
video-conferences with the chief investigator.
Dissemination
Outcomes will be reported in a peer reviewed journal
(publication target Journal of Psychopharmacology) and
will also be communicated at relevant conferences and
local newspapers for general audience.
Discussion
Depression remains a leading cause of morbidity and
mortality globally. Standard pharmacological treatments
often have poor response leading to diminished social and
functional outcomes. The consequential financial burdens
of untreated or partially treated depressive symptoms on
the individual and wider society are significant. Recent
studies indicate that anti-inflammatory treatments may
have some beneficial effects in depressive disorder. A pre-
vious open-label study and case reports indicate that the
use of minocycline as an adjunct to antidepressants may
provide some evidence of a reduction in depressive
symptoms.
To date there are no controlled clinical trials that have
investigated the use of minocycline for the treatment of
depressive symptoms. Our pilot randomised controlled
trial is the first of its nature and the findings from it may
contribute to evidence in the management of patients with
treatment resistant depressive symptoms. Should our re-
sults show a trend that minocycline reduces depressive
symptoms, we will use them to inform the develop-
ment of a larger trial. We hope that the current pilot
study will determine the feasibility of recruitment,
randomization, intervention implementation, blinded
assessment procedures and retention for a larger scale
hypothesis testing study. In the long term, we hope
the findings of this study will contribute to the treat-
ment of patients who suffer from prevalent and often
debilitating illness.
Trial status
This clinical trial was registered in October 2014. The
study is currently recruiting participants. The estimated
study completion date is August 2016. Please refer to this
study by its ClinicalTrials.gov identifier: NCT02263872.
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